About TargED
TargED is a company based in Utrecht (Netherlands) founded in 2020 by Marc Van Moorsel, Kristof Vercruysse, and Steven De Maat. TargED has raised $82.85 million across 5 funding rounds from investors including Andera Partners, Hadean Ventures and Sunstone. TargED offers products and services including TGD001. TargED operates in a competitive market with competitors including ALX Oncology, Alpine Immune Sciences, Alector, Hummingbird Bioscience and Shattuck Labs, among others.
- Headquarter Utrecht, Netherlands
- Founders Marc Van Moorsel, Kristof Vercruysse, Steven De Maat
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Targed Biopharmaceuticals B.V.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$82.85 M (USD)
in 5 rounds
-
Latest Funding Round
$25.23 M (USD), Series A
Dec 18, 2025
-
Investors
Andera Partners
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TargED
TargED offers a comprehensive portfolio of products and services, including TGD001.
Biological compound for targeted breakdown of blood clots in thrombosis.
Funding Insights of TargED
TargED has successfully raised a total of $82.85M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $25.23 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in TargED
TargED has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Andera Partners, Hadean Ventures and Sunstone.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Capital is provided to firms for growth, buyouts, and acquisitions.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investments are made by Sunstone in early-stage European companies.
|
Locked | Locked | Locked |
Investor details for TargED
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TargED
Investment portfolio details for TargED
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TargED
Detailed financials for TargED
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Targed Comparisons
Peer comparison for TargED
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TargED
TargED operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ALX Oncology, Alpine Immune Sciences, Alector, Hummingbird Bioscience and Shattuck Labs, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
ALX Oncology is focused on advancing cancer treatment therapies.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
|
| Locked | Locked | Locked |
Antibody drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| Locked | Locked | Locked |
Immunotherapies for cancer treatment are developed via proprietary antibody platform.
|
Detailed competitors of TargED
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Targed
Complete news archive for TargED
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TargED
TargED was founded in 2020.
TargED is headquartered in Utrecht, Netherlands.
Kristof Vercruysse is the current CEO of TargED. They have also founded this company.
TargED is a funded company, having raised a total of $82.85M across 5 funding rounds to date.
Developer of biological drugs for the treatment of thrombosis. The company offers its FDA-approved biological drugs and TargED Targeted Enzyme Delivery system which is a small antibody that can target the specific sites of thrombosis and enable the blood flow to reduce the risk for organ failure is reduced. The company target Thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS) and the lead compound Microlyse is a thrombolytic fusion protein that consisting two subunits i.e a nanobody domain targeting Von Willebrand Factor (VWF) which helps in wound healing also and the protease domain of the plasminogen activator urokinase. It targets the protease domain towards VWF, to active degradation of both VWF and fibrin.
TargED's top competitors include Alector, Hummingbird Bioscience and Alpine Immune Sciences.
TargED offers TGD001.
TargED has 10 investors. Key investors include Andera Partners, Hadean Ventures, Sunstone, BioGeneration Ventures, and Utrecht Holdings Seed Fund.